MRNJ Metatron Inc (PK)

Dover, DE -- November 21, 2017 -- InvestorsHub NewsWire -- Metatron (OTC PINK: MRNJ), a pioneer of releasing Marijuana & CBD related apps on iTunes and Google Play, is pleased to report that development of a new App called Bitmeet an ICO/Coin tracking and peer to peer crypto- coin transaction app in its final stages. Metatron inc. has developed over 2000 mobile apps for high profile client with millions in historical sales.

Completion and launch date of BitMeet app is forthcoming visit our new website: http://www.icocryptoblockchain.com for more information. Bitcoin

‘With literally hundreds of these Bitcoins trading and new ones coming in the Bitcoin market has seen a new surge in investors seeking out and trading these coins. Our new tracking/trading app will add considerable value to Metatron and increase our shareholder's investment in our company. Metatron’s ICO and peer to peer trading app BitMeet will monitor, locate and keep the traders of these Bitcoins informed and updated as new Coins enter the trading arena allowing users of our new ICO app to be a step ahead of the crowd and maximize trading opportunities with lower transaction costs in the Bitcoin marketplace” said, CEO Joe Riehl.

Metatron is also pleased to announce a formal offer to Buzzlink.com, a cannabis e-commerce platform for dispensaries and consumers. Buzzlink.com will be financed partially by the issuance of preferred B series shares.

Metatron approved investors can acquire Series B shares in blocks of various sizes starting at 1k and recently increased discounts. The first round investors will receive the highest discount. Series B shares can be redeemed through the Company, are immune to reverse splits, and will convert at 1 B share to 50,000 common shares at a discount. There are a limited number of B shares available and Metatron reserves the right to end offering at any time.

Details available at: http://metatroninc.com/series-b/

Metatron’s Apps:
iTunes: https://itunes.apple.com/us/artist/i-mobilize-inc./id325075390

Google Play: https://play.google.com/store/apps/developer? id=Metatron+Inc

Facebook: http://www.facebook.com/metatroninc Twitter: http://twitter.com/metatroninc
News: http://metatroninc.com/blog

Forward-Looking Statements:

Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results of the specific items described in this release, and the

company’s operations generally, to differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company’s need for additional financing, which is not assured and which may result in dilution of shareholders, the company’s status as a small company with a limited operating history, dependence on third parties and the continuing popularity of the iOS operating system, general market and economic conditions, technical factors, receipt of revenues, and other factors, many of which are beyond the control of the company. Although we believe that the expectations reflected in the forward- looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements, and we disclaim any obligation to update information contained in any forward-looking statement. Metatron does not grow, sell or distribute any substances that violate United States Law or the Controlled Substances Act.

Metatron, Inc. 302-861-0431 ir@metatroninc.com SOURCE: Metatron, Inc